Hager Biosciences
Hager Bio is a drug discovery and development company focused on small-molecule therapeutics for neuropsychiatric and neurological disorders. The organization develops multi-target small-molecule candidates using a discovery platform oriented to modulate complementary CNS signaling networks, and advances assets through preclinical safety assessments, patenting, and partnering activities.
Industries
Nr. of Employees
small (1-50)
Hager Biosciences
Patents
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12528819-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12291535-B2
View DetailsPyrazole and imidazole derivatives, compositions and methods as orexin antagonists
US-12275744-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12024525-B2
View Details
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12528819-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12291535-B2
View DetailsPyrazole and imidazole derivatives, compositions and methods as orexin antagonists
US-12275744-B2
View DetailsBenzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US-12024525-B2
View DetailsProducts
Small-molecule therapeutic candidates for substance use disorders (SUD)
Series of first-in-class small-molecule candidates designed to modulate multiple receptors implicated in craving, stress-induced relapse and insomnia.
Small-molecule therapeutic candidates for Alzheimer’s disease (AD)
Novel candidates designed to target neuromodulator circuits implicated in disrupted sleep architecture, impaired glymphatic clearance, neurodegeneration and psychotic symptoms.
Small-molecule therapeutic candidates for substance use disorders (SUD)
Series of first-in-class small-molecule candidates designed to modulate multiple receptors implicated in craving, stress-induced relapse and insomnia.
Small-molecule therapeutic candidates for Alzheimer’s disease (AD)
Novel candidates designed to target neuromodulator circuits implicated in disrupted sleep architecture, impaired glymphatic clearance, neurodegeneration and psychotic symptoms.
Services
Engagements for collaboration, licensing and partnering to advance discovery assets and clinical development.
Support and collaboration for advancing assets toward clinical development.
Engagements for collaboration, licensing and partnering to advance discovery assets and clinical development.
Support and collaboration for advancing assets toward clinical development.
Expertise Areas
- Small-molecule drug discovery
- Polypharmacology / multi-target therapeutic design
- Neuroscience and neuropsychiatric therapeutics
- Medicinal chemistry
Key Technologies
- Small-molecule discovery platforms
- Polypharmacology design strategies
- Receptor-targeted drug design
- Medicinal chemistry optimization
News & Updates
Announcement of multiple recently granted patents reflecting progression of discovery research and IP generation.
Announcement of multiple recently granted patents reflecting progression of discovery research and IP generation.